MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHSMEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHSMEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS

MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS

No trades
See on Supercharts

0A9G fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0A9G does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company